Recovery Insights Lab (RIL) proposes a partnership that combines our political-grade research methodology and segmentation expertise with Prodege's consumer panel infrastructure to build the first high-velocity, decision-grade behavioral health intelligence platform. RIL designs the instrument and interprets the data. Prodege fields it. The output is intelligence that holds up in a boardroom, courtroom, or congressional office — produced in weeks, not years.

The immediate proving ground: an Indivior engagement delivering real-world opioid use disorder (OUD) data to policy makers at the Recovery Summit in September. That engagement is the case study that proves the model — and the template for everything that follows.

Government data runs two to three years behind. Academic research moves at an academic pace. Pharmaceutical companies, payers, and policy makers are making consequential decisions on fragmented, outdated intelligence — and they know it.

The behavioral health field has never had access to the research infrastructure that decides elections and moves corporate strategy: large-scale survey operations, precision audience targeting, multivariate segmentation, and message testing calibrated for populations standard surveys were never designed to reach. That gap is the opportunity. Filling it requires panel reach RIL does not own — which is where Prodege comes in.

The capabilities Prodege does not have, and does not want to build:

• •Survey architecture & instrument design — sampling frames, question architecture, and response logic calibrated for hard-to-reach populations. No off-the-shelf instruments.
• •Multivariate segmentation — 50+ audience dimensions per respondent, with crosstab and longitudinal analysis across recovery pathway, duration, modality, and co-occurring conditions.
• •Public opinion & attitude modeling — 13 years of tracking how beliefs shift, what accelerates them, and what suppresses them.
• •Message architecture & testing — identifying what resonates, what backfires, and what reaches people no standard strategy gets to.
• •High-velocity data operations — political-cycle speed applied to behavioral health. Weeks where academia takes years.
• •Clinical depth & policy reach — a four-founder model that bridges research, clinical, and policy worlds so findings land in every audience that matters.

The reach RIL does not own, and does not want to replicate:

• •One of the largest, highest-quality consumer panels in the market.
• •Proven sampling infrastructure and engagement expertise.
• •Reach into audiences that standard research panels miss — including the behavioral health populations at the center of this work.
• •Incentive and engagement design that drives completion among hard-to-reach segments.

Prodege owns distribution. RIL owns interpretation. Neither is a commodity the other can easily replace.

This is not a survey-buying arrangement. It is a two-engine integration where each side does what it is best at, and the handoff between them is the product:

The combination is what makes the intelligence high-quality: rigorous methodology on the front end, premium panel execution in the middle, and decision-grade interpretation on the back end. Remove any layer and the output degrades to commodity survey data.

The first joint engagement is already in motion. Indivior has signaled that real-world OUD data needs to land in the hands of policy makers at the Recovery Summit in September. The specific audience and research objective are still being locked with Indivior; RIL has proposed six target segments (active MOUD patients, sustained recovery, treatment-naive, prescribers, family & caregivers, and payers/policy) and a working-backward timeline anchored to the Summit.

This engagement is the proving case. RIL designs and interprets; Prodege fields; the output is delivered to policy makers on deadline. Done well, it becomes the reference engagement that opens every subsequent conversation — with pharma, with payers, and with government.

• •Engagement model: per-study, with RIL as research lead and Prodege as panel partner. RIL owns the client relationship; Prodege is the fielding engine.
• •Commercial structure: Prodege compensated on a per-complete / panel-access basis per engagement; RIL retains research-design, analysis, and delivery fees. Open to a preferred-partner arrangement that simplifies every future engagement.
• •Strategic preference: a long-term panel partnership over one-off projects — a standing relationship that compounds across engagements and lets us move at the speed the field requires.
• •White-label option: Prodege can remain the named panel partner in joint deliverables, reinforcing Prodege's presence in the behavioral health category.

The behavioral health funding environment, the policy momentum around OUD, the September Summit, and the absence of any credible incumbent in this research category all align right now. The first partnership that fields credible, real-time behavioral health intelligence at scale will define the category. We would like that to be us — together.

1. Confirm scope of the Indivior pilot — segments, sample sizes, and timeline to the September Summit.
2. Agree the commercial structure for this engagement and, ideally, a preferred-partner framework for what follows.
3. Lock a working-backward timeline to field in August and deliver in early September.

We are ready to move immediately. The next conversation should align on the Indivior scope and the partnership terms so we can both field with confidence and deliver to policy makers on deadline.